Stereotaxis (STXS) Shares Outstanding (2010 - 2026)
Stereotaxis (STXS) posted quarterly Shares Outstanding (Entity) of $97.5 million for Q1 2026, up 13.38% year-over-year from $86.0 million in Q1 2025, and up 2.26% quarter-over-quarter from $95.3 million in Q4 2025.
Stereotaxis (STXS) Shares Outstanding (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Shares Outstanding (Entity) for 17 consecutive years, with $97.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 13.38% year-over-year to $97.5 million; the TTM figure through Mar 2026 stood at $97.5 million (up 13.38% YoY), while the FY2025 annual figure was $95.3 million, up 11.73% from the prior year.
- Shares Outstanding (Entity) climbed to $97.5 million in Q1 2026 per STXS's latest filing, from $95.3 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $97.5 million in Q1 2026 and bottomed at $74.6 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $82.8 million across 5 years, with a median of $82.1 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) increased 0.34% — and 2026, when it gained 13.38%.
- Stereotaxis' Shares Outstanding (Entity) stood at $74.9 million in 2022, then climbed by 8.11% to $80.9 million in 2023, then advanced by 5.41% to $85.3 million in 2024, then grew by 11.73% to $95.3 million in 2025, then increased by 2.26% to $97.5 million in 2026.
- Business Quant data shows STXS's Shares Outstanding (Entity) at $97.5 million in Q1 2026, $95.3 million in Q4 2025, and $91.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 354.10 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 274.79 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 486.70 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 145.52 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 857.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 70.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 172.70 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 195.00 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 517.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | 98.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.89 Mn |
| Mar 31, 2026 | 98.89 Mn |
| Dec 31, 2025 | 90.96 Mn |
| Sep 30, 2025 | 92.01 Mn |
| Jun 30, 2025 | 87.95 Mn |
| Mar 31, 2025 | 87.77 Mn |
| Dec 31, 2024 | 85.18 Mn |
| Sep 30, 2024 | 85.82 Mn |
| Jun 30, 2024 | 84.57 Mn |
| Mar 31, 2024 | 83.48 Mn |
| Dec 31, 2023 | 80.70 Mn |
| Sep 30, 2023 | 82.47 Mn |
| Jun 30, 2023 | 81.05 Mn |
| Mar 31, 2023 | 76.50 Mn |
| Dec 31, 2022 | 76.06 Mn |
| Sep 30, 2022 | 76.10 Mn |
| Jun 30, 2022 | 75.95 Mn |
| Mar 31, 2022 | 75.88 Mn |
| Dec 31, 2021 | 75.56 Mn |
| Sep 30, 2021 | 75.70 Mn |